trisomy 21

The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.

The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.

The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.

The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.

The company is now seeking commercial partners in Brazil to make the Iona test available in the country.

Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.

Limited Access

Poor women have limited access to noninvasive prenatal screening tools, a post at Health Affairs' blog says.

The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.

The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.

Reuters reports that UK researchers have tested a new approach to screening for Down syndrome and other chromosomal disorders.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.